Michel Ducreux

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 10

Top Topics

Top Venues

Future oncology (London, England)

British journal of cancer

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Philip A Philip, Vaibhav Sahai, Nathan Bahary, Amit Mahipal, Anup Kasi Loknath Kumar, Caio Max S Rocha Lima, Angela T Alistar, Paul E Oberstein, Talia Golan, Jean-Phillippe Metges, Jill Lacy, Christos Fountzilas, Charles D Lopez, Michel Ducreux, Pascal Hammel, Mohamed E Salem, David Bajor, Al Bowen Benson, Sanjeev Luther, Timothy Pardee, Eric Van Cutsem
Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Neil H Segal, Jeanne Tie, Scott Kopetz, Michel Ducreux, Eric Chen, Rodrigo Dienstmann, Antoine Hollebecque, Matthew J Reilley, Elena Elez Fernandez, Jan Cosaert, Jason Cain, Yee Soo-Hoo, Nicola Hewson, Zachary A Cooper, Rakesh Kumar, Josep Tabernero
COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer. British journal of cancer (2024)
Raefa Abou Khouzam, Jean-Marie Lehn, Hemma Mayr, Pierre-Alain Clavien, Michael Bradley Wallace, Michel Ducreux, Perparim Limani, Salem Chouaib
Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy. Cancers 15 (4) (2023)
Raefa Abou Khouzam, Jean-Marie Lehn, Hemma Mayr, Pierre-Alain Clavien, Michael Bradley Wallace, Michel Ducreux, Perparim Limani, Salem Chouaib
Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy. Cancers 15 (4) (2023)
Raefa Abou Khouzam, Jean-Marie Lehn, Hemma Mayr, Pierre-Alain Clavien, Michael Bradley Wallace, Michel Ducreux, Perparim Limani, Salem Chouaib
Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy. Cancers 15 (4) (2023)
Charlotte Canet-Jourdan, Diane-Laure Pagès, Clémence Nguyen-Vigouroux, Jérôme Cartry, Olivier Zajac, Christophe Desterke, Jean-Baptiste Lopez, Emie Gutierrez-Mateyron, Nicolas Signolle, Julien Adam, Joel Raingeaud, Mélanie Polrot, Patrick Gonin, Jacques R R Mathieu, Sylvie Souquere, Gerard Pierron, Maximiliano Gelli, Peggy Dartigues, Michel Ducreux, Valeria Barresi, Fanny Jaulin
Patient-derived organoids identify an apico-basolateral polarity switch associated with survival in colorectal cancer. Journal of cell science 135 (14) (2022)
Jean-Phillippe Metges, Dominique Genet, David Tougeron, Catherine Ligeza, Michel Ducreux, Christophe Borg, Rosine Guimbaud, Jean Marc Phelip, Louis-Marie Dourthe, Stefano Kim
Real-world safety and effectiveness of regorafenib in metastatic colorectal cancer: the French CORRELATE cohort. Future oncology (London, England) 17 (25) (2021)
Caroline Touloupas, Matthieu Faron, Julien Hadoux, Frédéric Deschamps, Charles Roux, Maxime Ronot, Steven Yevich, Julien Joskin, Maximiliano Gelli, Rémy Barbé, Livia Lamartina, Hubert Tissot, Jean Yves Scoazec, David Malka, Michel Ducreux, Eric Baudin, Thierry de Baère, Lambros Tselikas
Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience. Cancers 13 (21) (2021)
Alice Boilève, Loïc Verlingue, Antoine Hollebecque, Valérie Boige, Michel Ducreux, David Malka
Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers. Expert opinion on investigational drugs 30 (4) (2021)
Cristina Smolenschi, Audrey Perret, François Dall'Armellina, Valerie Boige, David Malka, Antoine Hollebecque, Michel Ducreux
An appraisal of emerging second line therapies for metastatic colorectal cancer. Expert review of gastroenterology & hepatology 15 (2) (2020)